NOTES: Hidden We need to think about streamlining these so that they're consistently headline or sentence capsed
0 Best Practices - Expand the formula bar so that you don't miss the additional info found in some of the cells. Reference the image to the right for more help. - Use filters to explore and organize the information for your own use. When accessing through this view-only link, filters are temporary to that search/find. - This document is also available for download under the File tab. - To find the latest additions or updates to the tracker, command+F or control+F and search for an asterisk. All cells with new information have an added at the end. Last Update: May 21, 2020 | 12:37 pm ET © 2020 Milken Institute00 2020
Number Treatment vs. Vaccine Product Category Product Description Stage of Development Anticipated Next Steps Clinical Trials for COVID-19 Developer / Researcher Funder Published Results Clinical Trials for Other Diseases (T only) Related Use / Platform (V Only) FDA-Approved Indications Sources Date Last Updated
1 Treatment Antibodies Polyclonal hyperimmune globulin (H-IG), unbranded Pre-clinical Phase 1 trials start in summer 2020. To patients between December 2020 and December 2021 CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot) N/A Sources 5/10/2020 N/A Sources 5/10/2020
2 Treatment Antibodies Antibodies from mice, REGN3048-3051, against the spike protein Pre-clinical Start Phase 1 June 2020 Regeneron Biomedical Advanced Research and Development Authority (BARDA) N/A Sources Prior to 4/20/2020 N/A Sources Prior to 4/20/2020
3 Treatment Antibodies CT-P59; Antibodies from recovered COVID-19 patients Pre-clinical Start Phase 1 in July 2020 Celltrion The Korea Health Industry Development Institute N/A Sources 5/14/2020 N/A Sources 5/14/2020
4 Treatment Antibodies Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2 Pre-clinical Celltrion N/A Sources Prior to 4/20/2020 N/A Sources Prior to 4/20/2020
5 Treatment Antibodies COVI-SHIELD antibody cocktail that binds to three different epitopes Pre-clinical Start Phase 2 trial 3Q 2020 Sorrento Therapeutics/ Mount Sinai Health System N/A Sources 5/20/2020 N/A Sources 5/20/2020
7 Treatment Antibodies Antibodies from recovered COVID-19 patients Pre-clinical Kamada/ Kedrion Biopharma N/A Sources 5/4/2020 N/A Sources 5/4/2020
8 Treatment Antibodies VIR-7831 and VIR-7832, antibodies from recovered SARS patients Pre-clinical Start Phase 2 ~ July-September 2020 Vir Biotechnology/GSK/ Samsung/WuXi Biologics/Biogen N/A Sources 5/20/2020 N/A Sources 5/20/2020
9 Treatment Antibodies Antibodies from recovered COVID-19 patients Pre-clinical Start Phase 1 in late July 2020 Eli Lilly/Ab-Cellera (NIH Vaccines Research Center) Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund) N/A Sources 5/5/2020 N/A Sources 5/5/2020
10 Treatment Antibodies COVID-19 Immunoglobulin, plasma derived Pre-clinical CSL Behring Australia N/A Sources 5/10/2020 N/A Sources 5/10/2020
Treatment Antibodies Avastin (bevacizumab), vascular endothelial growth factor inhibitor Clinical Phase 2/3 studies recruiting April 2020 NCT04275414 NCT04305106 NCT04344782 Numerous trials with Chinese research sponsors; Roche FDA-approved since 2004, approved to treat certain types of cancer Sources 4/27/2020 FDA-approved since 2004, approved to treat certain types of cancer Sources 4/27/2020
11 Treatment Antibodies PD-1 blocking antibody; Thymosin Clinical Phase 2 study not yet recruiting NCT04268537 ChiCTR2000030028 Numerous trials with Chinese research sponsors Unknown Sources 4/27/2020 Unknown Sources 4/27/2020
12 Treatment Antibodies Opdivo (nivolumab), PD-1 blocking antibody Clinical Phase 2 study not yet recruiting NCT04356508 NCT04333914 University of Hong Kong (BMS) FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer Sources 4/27/2020 FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer Sources 4/27/2020
13 Treatment Antibodies leronlimab (PRO 140), a CCR5 antagonist Clinical / Compassionate Use Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020 NCT04343651 NCT04347239 CytoDyn CytoDyn Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers N/A Sources Prior to 4/20/2020 N/A Sources Prior to 4/20/2020
14 Treatment Antibodies AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody Clinical No trial updates since February 2020 ChiCTR2000029806 Wuhan Jinyintan Hospital Treatment of certain cancers N/A Sources 4/27/2020 N/A Sources 4/27/2020
15 Treatment Antibodies Kevzara (sarilumab), interleukin-6 receptor antagonist Clinical Started phase 2/3 in March 2020; preliminary Phase 2 results released April 27, 2020, trial continuing for only critical patients, Phase 3 (US) results expected June 2020, Phase 3 (ex-US) results expected 3Q 2020 NCT04315298 NCT04321993 NCT04341870 NCT04324073 NCT04327388 NCT04322773 NCT04345289 NCT02735707 NCT04357808 NCT04357860 NCT04359901 Sanofi/Regeneron; Feinstein Institutes; REMAP-CAP global trial Biomedical Advanced Research and Development Authority (BARDA) medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive) ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.05.14.20094144) FDA-approved since 2017, approved to treat rheumatoid arthritis Sources 5/20/2020 FDA-approved since 2017, approved to treat rheumatoid arthritis Sources 5/20/2020
16 Treatment Antibodies Actemra (tocilizumab), interleukin-6 receptor antagonist Clinical Roche studies could be completed May or June 2020; Phase 2 open label study in Italy active (April 2020), Phase 3 studies recruiting April 2020, some results from open label study in France released April 2020 NCT04317092 NCT04320615 NCT04310228 ChiCTR2000030894 NCT04306705 ChiCTR2000030442 ChiCTR2000029765 NCT04322773 NCT04345445 NCT04331795 NCT04332094 NCT04346355 NCT04359667 NCT04332913 NCT04335071 NCT04356937 NCT04361032 NCT04315480 NCT04339712 NCT04333914 NCT04361552 NCT04330638 NCT04331808 NCT02735707 NCT04349410 NCT04363736 NCT04372186 NCT04363853 Numerous trials with global research sponsors; Roche; REMAP-CAP Biomedical Advanced Research and Development Authority (BARDA) ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.04.20.20061861) medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid) PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1) medRxiv (https://doi.org/10.1101/2020.05.01.20078360) medRxiv (https://doi.org/10.1101/2020.05.07.20094599) medRxiv (https://doi.org/10.1101/2020.05.14.20099234) medRxiv (https://doi.org/10.1101/2020.05.13.20100404) medRxiv (https://doi.org/10.1101/2020.05.13.20100081) FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome Sources 5/21/2020 FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome Sources 5/21/2020
17 Treatment Antibodies Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal Clinical Phase 2 study started in April 2020 NCT04351243 Roivant Sciences N/A Sources 5/14/2020 N/A Sources 5/14/2020
18 Treatment Antibodies TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody Clinical Phase 1/2 recruiting April 2020 NCT04341116 I-Mab Biopharma N/A Sources 4/27/2020 N/A Sources 4/27/2020
19 Treatment Antibodies lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody Clinical / Compassionate Use Phase 3 not yet recruiting April 2020 NCT04351152 Humanigen Inc. Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma N/A Sources 4/27/2020 N/A Sources 4/27/2020
20 Treatment Antibodies Sylvant (siltuximab), interleukin-6 targeted monoclonal Clinical / Compassionate Use Compassionate use data shared April 2020; Phase 3 recruiting April 2020 NCT04322188 NCT04330638 NCT04329650 EUSA Pharma/The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/) medRxiv (https://doi.org/10.1101/2020.04.01.20048561) medRxiv (https://doi.org/10.1101/2020.04.23.20076612) FDA-approved since 2014, approved to treat multicentric Castleman disease Sources 4/28/2020 FDA-approved since 2014, approved to treat multicentric Castleman disease Sources 4/28/2020
21 Treatment Antibodies Soliris (eculizumab), complement inhibitor Clinical/ Expanded access Phase 2 recruiting May 2020 NCT04288713 NCT04346797 NCT04355494 Assistance Publique - Hopitaux de Paris (Phase 2); Alexion (Expanded Access) FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder Sources 5/5/2020 FDA-approved since 2007, approved to treat Par